Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

With a well characterized genetic driver, a clear marker to show whether it's working, and available treatments that carry high annual costs, hemophilia may be a good testing ground for commercializing gene therapy, but payers still have to work out how to reimburse the one-time medicines.

Regenerative Medicine Blood & Coagulation Disorders

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

With the first few cell and gene therapies launched in the US, the challenge of pricing and reimbursement – and the opportunity to set the standards in this area – was a repeated theme at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa.

Reimbursement Regenerative Medicine

Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor

The three US FDA-approved anti-CGRP antibodies for migraine prevention have similar efficacy and matching prices, but Lilly thinks access to Emgality – including through value-based arrangements – along with the biologic's ease of use and headache-free data will differentiate the product.

Approvals Launches

Interview: DKSH Building Healthcare Services In Changing Asian Markets

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.

Asia Pacific Business Strategies

Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price

But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.

Market Access Metabolic Disorders

Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says

Citing need for more ‘pull’ incentives to overcome commercial hurdles, FDA commissioner says a subscription-based fee reimbursement system would provide a foundation for return on investment of new antimicrobials targeting multi-drug resistant pathogens.

Infectious Diseases Reimbursement

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

Market Access Pricing Debate

ImmuPharma Still Upbeat About Lupuzor But Market Unconvinced

The UK biotech is expanding access to its unapproved lupus drug, has signed a licensing deal with Incantera and unveiled plans to divest its metabolic disorder subsidiary Ureka but fears about ImmuPharma's future remain.

Immune Disorders Clinical Trials

Manchester United With Big Pharma On Improving Outcomes

The English city's desire to collaborate with the pharmaceutical industry to come up with cost-effective solutions to treat long-term chronic diseases has seen Manchester emerge as a closely watched experiment for the future of health care.

Market Access Healthcare Systems
See All
Advertisement
UsernamePublicRestriction

Register